UPDATE: Pareto Securities Downgrades AstraZeneca to Sell
Pareto Securities reduced its rating on AstraZeneca (NYSE: AZN) from Hold to Sell and lowered its price target from $48 to $44.
Pareto Securities noted, "AstraZeneca (AZN) did not surprise on revenues although margins overall were stronger than consensus expectations. The appointment of a new CEO and recent deals have lifted the valuation to new highs. We do not believe this is sustainable in the short term as 2013E numbers are not strong enough."
AstraZeneca closed at $46.70 on Thursday.
Latest Ratings for AZN
|Dec 2016||Leerink Swann||Upgrades||Market Perform||Outperform|
|Sep 2016||PiperJaffray||Initiates Coverage on||Overweight|
|Sep 2016||Exane BNP Paribas||Downgrades||Outperform||Neutral|
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.